Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYSTEROXINE study of hysteroscopic intramyometrial botulinum toxin for severe primary dysmenorrhea
2025-520638-53-00Phase 3Authorised
- Sponsor
- CHU de Nantes
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary dysmenorrhea (PD) comparing Xeomin intramyometrial injection with Placebo intramyometrial injection (2 arms). Primary endpoint: PGI-I response at 3 months. Planned start Jul 2025; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
primary dysmenorrhea (PD)
Beyond the preview
Go deeper on 2025-520638-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520638-53-00.